These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38938625)

  • 1. Balancing medical innovation and affordability in the new healthcare ecosystem in China: Review of pharmaceutical pricing and reimbursement policies.
    Chen V; Shao W
    Health Care Sci; 2023 Dec; 2(6):381-391. PubMed ID: 38938625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The challenge of healthcare big data to China's commercial health insurance industry: evaluation and recommendations.
    Wu J; Qiao J; Nicholas S; Liu Y; Maitland E
    BMC Health Serv Res; 2022 Sep; 22(1):1189. PubMed ID: 36138390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Policy Updates on Access to and Affordability of Innovative Medicines in China.
    Liu GG; Wu J; He X; Jiang Y
    Value Health Reg Issues; 2022 Jul; 30():59-66. PubMed ID: 35235902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asian innovation in pharmaceutical and medical device industry - beyond tomorrow.
    Jakovljevic M; Wu W; Merrick J; Cerda A; Varjacic M; Sugahara T
    J Med Econ; 2021 Nov; 24(sup1):42-50. PubMed ID: 34915798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does China's national volume-based drug procurement policy promote or hinder pharmaceutical innovation?
    Li X; Xu J
    Front Pharmacol; 2024; 15():1392239. PubMed ID: 38994196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement.
    Macabeo B; Wilson L; Xuan J; Guo R; Atanasov P; Zheng L; François C; Laramée P
    J Mark Access Health Policy; 2023; 11(1):2218633. PubMed ID: 37325810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare reform in the United States and China: pharmaceutical market implications.
    Daemmrich A; Mohanty A
    J Pharm Policy Pract; 2014; 7(1):9. PubMed ID: 25097759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical Insurance Information Systems in China: Mixed Methods Study.
    Li Y; Lu C; Liu Y
    JMIR Med Inform; 2020 Sep; 8(9):e18780. PubMed ID: 32673209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of China's medical biotech industry needs to be driven by innovation.
    Yu Z; Dai Y
    Biotechnol J; 2006 Nov; 1(11):1253-7. PubMed ID: 17068752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
    Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
    Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region.
    Chen Y; Schweitzer SO
    Value Health; 2008 Mar; 11 Suppl 1():S124-9. PubMed ID: 18387056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research on the impact of China's reform to delegate power, streamline administration, and optimize government services on the technology innovation efficiency of the pharmaceutical manufacturing industry.
    Gu Y; Zhuang Q
    Front Public Health; 2024; 12():1325298. PubMed ID: 38344238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reimbursement decision speed for oncology new drugs in China and its determinant factors.
    Zhu X; Chen Y
    Front Public Health; 2023; 11():1207739. PubMed ID: 38026304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Medical Service Pricing in China's Healthcare System: Challenges, Constraints, and Policy Recommendations.
    Xiong W; Deng Y; Yang Y; Zhang Y; Pan J
    Front Public Health; 2021; 9():787865. PubMed ID: 34900924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries.
    Atikeler EK; Özçelikay G
    Springerplus; 2016; 5(1):1876. PubMed ID: 27833835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Market access and value-based pricing of digital health applications in Germany.
    Gensorowsky D; Witte J; Batram M; Greiner W
    Cost Eff Resour Alloc; 2022 Jun; 20(1):25. PubMed ID: 35698135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.